TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that further to its press release on January 13, 2026, it has closed the first tranche of its previously announced non-brokered private placement for gross proceeds of $3,110,000 (the “First Tranche”). Under t ...

TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, is pleased to announce a non-brokered private placement of up to 3,500,000 units of the Company (the “Units”) at a price of $1.00 per Unit, for aggregate gross proceeds of up to $3,500,000 CDN (the “Offering”). Each Unit will ...

Core Insights - NetraMark Holdings Inc. has made significant progress in commercial execution, regulatory engagement, and scientific validation, strengthening its growth trajectory in AI-driven clinical trial optimization [1][2] Group 1: Contract Backlog and Financial Outlook - The contract backlog for NetraMark increased to approximately C$2.5 million, driven by new project commitments and commercial momentum, with a target of reaching C$8–$10 million by mid-2026 [2][4] - The company is experiencing growing commercial traction and expanding channel partnerships, which support its financial outlook [4] Group 2: Regulatory Engagement - NetraMark completed a Critical Path Innovation Meeting (CPIM) with the FDA, receiving feedback on its NetraAI platform and its application in clinical trial design [2] - The FDA discussed considerations for identifying responder-enriched subgroups while maintaining control of Type I error, aligning with FDA enrichment guidance [2] Group 3: Scientific Validation - A scientific study on NetraAI was accepted for publication in npj Digital Medicine, demonstrating its ability to identify clinically meaningful subgroups in a Phase II depression trial [2] - The acceptance by a high-impact journal provides third-party validation of NetraMark's scientific approach [2] Group 4: Strategic Collaborations - NetraMark secured an Ontario Research Fund – Research Excellence Award in collaboration with the Centre for Addiction and Mental Health (CAMH), focusing on analyzing genetic and epigenetic data in psychiatric disorders [2] - This collaboration aims to enhance NetraAI's capabilities in identifying explainable patient subpopulations [2]

Core Insights - NetraMark Holdings Inc. has been awarded the Ontario Research Fund - Research Excellence Award in collaboration with the Centre for Addiction and Mental Health (CAMH) for their innovative partnership in advancing research and technology in mental health [1][2]. Group 1: Collaboration and Research Focus - The collaboration will utilize NetraAI, a machine learning platform, to analyze genetic and epigenetic data from studies on schizophrenia and major depressive disorder [2][3]. - The initiative aims to identify explainable patient subpopulations to clarify biological subtypes in psychiatric disorders, supporting next-generation precision treatment strategies [3]. Group 2: Technological Advancements - NetraAI is designed to separate small datasets into explainable and unexplainable subsets, enhancing the accuracy of insights derived from clinical trials [6]. - The platform's unique focus mechanisms aim to reduce the risk of overfitting, which can lead to inaccurate insights and improve the chances of clinical trial success [6]. Group 3: Impact on Clinical Trials - The collaboration is expected to enhance NetraAI's capabilities to serve pharmaceutical sponsors, ultimately improving clinical trial outcomes in the psychiatric space [3][4]. - The research will also evaluate additional datasets from the Ontario Health Insurance Plan (OHIP) to analyze cost-effectiveness and the broader health-system impact of personalized patient care [4]. Group 4: Institutional Background - CAMH is recognized as Canada's largest mental health and addiction teaching hospital, combining clinical care, research, education, and policy development to transform the lives of individuals affected by mental illness [5]. - The partnership with CAMH allows NetraMark to leverage extensive genomic and clinical datasets to explore genetic influences on treatment responses [4]. Group 5: Company Overview - NetraMark focuses on developing Generative Artificial Intelligence and Machine Learning solutions specifically for the pharmaceutical industry, utilizing a novel algorithm to parse patient data effectively [7]. - The company's approach enables accurate segmentation of diseases and classification of patients based on treatment sensitivity and efficacy [7].

Core Insights - NetraMark Holdings Inc. has completed its Critical Path Innovation Meeting (CPIM) with the FDA, discussing its AI platform, NetraAI, and its potential in clinical trial design [1][2][4] - The FDA provided feedback on NetraAI's explainable AI/ML capabilities and suggested exploring the Model-Informed Drug Development (MIDD) Paired Meeting Program for further regulatory dialogue [2][3][4] Company Overview - NetraMark is focused on developing AI and machine learning solutions for the pharmaceutical industry, utilizing a novel algorithm to analyze patient datasets effectively [6] - The company's platform, NetraAI, is designed to identify biological and clinical signatures in small datasets, enhancing the likelihood of clinical trial success [2][5] Regulatory Engagement - The CPIM with the FDA is a significant step for NetraMark, providing insights into regulatory considerations for AI in clinical development [4] - The FDA's engagement reinforces the importance of explainability and scientific rigor in AI applications for drug development [2][3] Technical Differentiation - NetraAI employs unique focus mechanisms to separate explainable and unexplainable subsets of data, addressing challenges like overfitting that can compromise trial outcomes [5] - The platform's approach allows for targeted inclusion/exclusion criteria and pre-specified stratification in trial designs, potentially improving statistical power and reducing trial risks [3][4]

Core Insights - NetraMark Holdings Inc. has secured a new contract with a global biopharmaceutical company to provide analytics support for a pivotal Phase 3 clinical trial, highlighting the company's growing influence in the pharmaceutical sector [1][2]. Group 1: Contract and Project Details - The new engagement is part of an existing master services agreement and represents a discrete project aimed at enhancing decision support in Phase 3 trials, showcasing the increasing interest in NetraAI technology [2][4]. - NetraMark will utilize its NetraAI platform to identify and characterize patient subpopulations, including responders and non-responders, which will aid in interpreting treatment response patterns and variability within the study population [3][4]. Group 2: Technology and Methodology - NetraAI is designed to separate small datasets into explainable and unexplainable subsets, which helps avoid overfitting and enhances the accuracy of insights derived from clinical trials [5][6]. - The technology's unique focus mechanisms allow for better segmentation of diseases and classification of patient responses, thereby increasing the likelihood of clinical trial success [5][6]. Group 3: Company Position and Future Outlook - The CEO of NetraMark emphasized the growing trust from biopharmaceutical companies in the value of explainable AI for high-stakes development programs, indicating a positive trajectory for the company's future engagements [4][7]. - This contract reinforces NetraMark's position in AI-powered clinical trial optimization and suggests potential for further growth as the company becomes integrated into standard operating procedures of biopharmaceutical firms [4][7].

Core Insights - NetraMark Holdings Inc. has announced the acceptance of its peer-reviewed paper on its AI platform, NetraAI, for publication in npj Digital Medicine, highlighting its advancements in clinical trial analytics [1][3] Group 1: Publication and Research Findings - The paper demonstrates how NetraAI utilizes explainable AI to identify patient subpopulations that enhance therapeutic responses in clinical trials, specifically using data from a Phase II ketamine trial for treatment-resistant depression [2][3] - The research was co-authored by experts from the National Institute of Mental Health and NetraMark, showcasing a collaborative effort in advancing AI applications in clinical settings [3] - The publication emphasizes the integration of advanced modeling techniques within NetraAI, which aims to improve clinical trial decision-making and reduce placebo effects [4] Group 2: Technology and Methodology - NetraAI is designed to differentiate between explainable and unexplainable patient subsets, addressing issues of overfitting that can lead to inaccurate insights in clinical trials [6] - The platform employs a novel topology-based algorithm that allows for effective segmentation of patient data, enhancing the accuracy of treatment efficacy assessments [7] - By focusing on smaller datasets, NetraAI aims to improve the chances of clinical trial success through better patient classification and treatment response predictions [6][7]

Core Insights - NetraMark Holdings Inc. has signed four contracts with a leading global pharmaceutical company to provide advanced AI analytics for multiple late-stage clinical studies [1][4] - The proprietary NetraAI platform will be utilized to analyze clinical data from these studies, focusing on identifying patient subpopulations that influence treatment and placebo responses [2][3] Group 1: Contract Details - The contracts represent a significant expansion of the ongoing collaboration between NetraMark and the pharmaceutical company, reflecting continued confidence in NetraMark's technology [3][4] - Each study will leverage the NetraAI system, which is designed to identify high-effect-size subgroups within complex datasets, aligning with FDA expectations for explainable AI in clinical development [3][5] Group 2: Technology Overview - NetraAI is engineered to separate small datasets into explainable and unexplainable subsets, enhancing the accuracy of insights derived from clinical data [5][6] - The technology allows for the analysis of smaller datasets while accurately classifying patients based on their sensitivity to drugs and treatment efficacy [6]

Core Insights - NetraMark Holdings Inc. has signed a contract with a leading biopharmaceutical company to utilize its NetraAI platform in a Phase 3 clinical trial for a new psychiatric medicine, indicating the company's growing influence in the pharmaceutical industry [1][2]. Company Overview - NetraMark is focused on transforming clinical trials through AI-powered precision analytics, specifically targeting the pharmaceutical sector [1][6]. - The company employs a unique topology-based algorithm that allows for effective analysis of small, complex clinical datasets, enhancing the understanding of patient heterogeneity [6]. Technology and Methodology - The NetraAI platform utilizes a dynamical systems framework to analyze multi-dimensional clinical data, identifying explainable subpopulations related to treatment responses and adverse events [2][3]. - Unlike traditional AI methods, NetraAI incorporates focus mechanisms that separate datasets into explainable and unexplainable subsets, reducing the risk of overfitting and improving the accuracy of insights [5]. Industry Impact - The engagement with the biopharmaceutical company reflects a growing recognition of the value of explainable AI in improving clinical trial success rates [3][4]. - NetraMark's technology aims to provide actionable insights that can inform regulatory and market access strategies, thereby supporting drug development success [2][4].

Core Insights - NetraMark Holdings Inc. is leveraging its AI technology, NetraAI, to enhance clinical trials in the pharmaceutical industry, particularly for major depressive disorder (MDD) [1][10] Group 1: Presentation Highlights - At the ISCTM Autumn conference and ECNP Congress, NetraMark showcased two significant applications of its technology, focusing on ketamine and escitalopram trials [1][5] - The first presentation demonstrated how NetraAI identified distinct patient responder subgroups in ketamine trials, revealing that ketamine responders had unique baseline characteristics compared to placebo responders [2][3] - The second presentation introduced a novel algorithm that improved predictive accuracy in heterogeneous MDD trials, specifically for escitalopram response, by identifying a compact feature set related to anhedonia and mood [5][6] Group 2: Key Findings - In the ketamine trial, responder subgroups diverged significantly from placebo responders by the second infusion, indicating that ketamine's efficacy is not merely due to functional unblinding [4][8] - NetraAI's analysis in the CAN-BIND trial reduced clinical variables from 718 to 8 key variables, enhancing prediction accuracy and identifying a subgroup of highly predictive responders [9][7] - The technology revealed a genetic signature linked to neuroplasticity, allowing for a 91% accuracy in predicting treatment success when retrained on specific features [17] Group 3: Implications for Clinical Trials - NetraAI's capabilities can help overcome traditional barriers in CNS drug development by improving patient stratification, reducing placebo-related noise, and enhancing predictive modeling [10][12] - The advancements in distinguishing true pharmacologic effects from placebo responses represent a significant step forward in the design and interpretation of psychiatric and CNS trials [11][12] - As precision medicine becomes increasingly important, NetraMark's innovations provide a robust toolkit for pharmaceutical companies to uncover meaningful patient subgroups and accelerate drug development timelines [12][14]